Innospec Stock Price, News & Analysis (NASDAQ:IOSP)

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec announced a Semi-Annual dividend on Tuesday, May 7th. Investors of record on Tuesday, May 21st will be given a dividend of $0.50 per share on Thursday, May 30th. This represents a yield of 1.18%. The ex-dividend date of this dividend is Monday, May 20th. View Innospec's Dividend History.

Innospec Inc. (NASDAQ:IOSP) issued its quarterly earnings data on Tuesday, August, 6th. The specialty chemicals company reported $1.12 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.10 by $0.02. The specialty chemicals company had revenue of $362.40 million for the quarter, compared to analysts' expectations of $371.20 million. Innospec had a return on equity of 15.11% and a net margin of 6.10%. The company's revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.80 EPS. View Innospec's Earnings History.

Innospec is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Innospec.

2 brokers have issued 1 year price objectives for Innospec's stock. Their predictions range from $83.00 to $95.00. On average, they expect Innospec's share price to reach $89.00 in the next year. This suggests that the stock has a possible downside of 2.6%. View Analyst Price Targets for Innospec.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innospec.

Media coverage about IOSP stock has been trending negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Innospec earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media stories about the specialty chemicals company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Innospec.

Innospec saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 310,600 shares, a decrease of 17.2% from the July 31st total of 375,100 shares. Based on an average daily volume of 117,300 shares, the short-interest ratio is currently 2.6 days. Approximately 1.3% of the shares of the company are sold short. View Innospec's Current Options Chain.

Some companies that are related to Innospec include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Ingevity (NGVT), Balchem (BCPC), Olin (OLN), Chemours (CC), PQ Group (PQG), GCP Applied Technologies (GCP), Innophos (IPHS), Loop Industries (LOOP) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Intellia Therapeutics (NTLA), NVIDIA (NVDA), Applied Materials (AMAT), Broadcom (AVGO), Lam Research (LRCX), Boeing (BA), Colgate-Palmolive (CL), XPO Logistics (XPO), Zayo Group (ZAYO) and Adobe (ADBE).

Innospec's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.93%), BlackRock Inc. (16.92%), Vanguard Group Inc. (10.52%), Wells Fargo & Company MN (4.99%), Price T Rowe Associates Inc. MD (2.49%) and Northern Trust Corp (2.27%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, David Earl Williams, Hugh Aldous, Ian Cleminson, Ian Malcolm Mcrobbie, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Institutional Ownership Trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including Westwood Holdings Group Inc., First Wilshire Securities Management Inc., Eagle Asset Management Inc., SG Americas Securities LLC, James Investment Research Inc., Emerald Advisers LLC, Kirr Marbach & Co. LLC IN and Acadian Asset Management LLC. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Ian Cleminson, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Insider Buying and Selling for Innospec.

IOSP stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Wasatch Advisors Inc., Jacobs Levy Equity Management Inc., Northern Trust Corp, Wells Fargo & Company MN and Zacks Investment Management. View Insider Buying and Selling for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $91.41.

Innospec has a market capitalization of $2.24 billion and generates $1.48 billion in revenue each year. The specialty chemicals company earns $85 million in net income (profit) each year or $4.83 on an earnings per share basis. Innospec employs 2,000 workers across the globe.View Additional Information About Innospec.

The official website for Innospec is http://www.innospecinc.com/.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]